It's been a pretty great week for Nephros, Inc. (NASDAQ:NEPH) shareholders, with its shares surging 15% to US$3.52 in the week since its latest first-quarter results. It was a workmanlike result, with revenues of US$5.2m coming in 4.4% ahead of expectations, and statutory earnings per share of US$0.01, in line with analyst appraisals. Earnings are an important time for investors, as they can track a company's performance, look at what the analyst is forecasting for next year, and see if there's been a change in sentiment towards the company. We thought readers would find it interesting to see the analyst latest (statutory) post-earnings forecasts for next year.

After the latest results, the single analyst covering Nephros are now predicting revenues of US$21.0m in 2026. If met, this would reflect a decent 9.8% improvement in revenue compared to the last 12 months. Statutory earnings per share are expected to descend 18% to US$0.06 in the same period. Before this earnings report, the analyst had been forecasting revenues of US$20.5m and earnings per share (EPS) of US$0.15 in 2026. So it's pretty clear the analyst has mixed opinions on Nephros after the latest results; even though they upped their revenue numbers, it came at the cost of a large cut to per-share earnings expectations.

The analyst also upgraded Nephros' price target 27% to US$7.00, implying that the higher revenue expected to generate enough value to offset the forecast decline in earnings.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We can infer from the latest estimates that forecasts expect a continuation of Nephros'historical trends, as the 13% annualised revenue growth to the end of 2026 is roughly in line with the 15% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 6.1% per year. So it's pretty clear that Nephros is forecast to grow substantially faster than its industry.

The Bottom Line

The most important thing to take away is that the analyst downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analyst clearly feeling that the intrinsic value of the business is improving.

With that in mind, we wouldn't be too quick to come to a conclusion on Nephros. Long-term earnings power is much more important than next year's profits. At least one analyst has provided forecasts out to 2027, which can be seen for free on our platform here.

That said, it's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Nephros , and understanding this should be part of your investment process.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.